Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome.

H. S. Singer, L. E. Tune, I. J. Butler, R. Zaczek, J. T. Coyle

Research output: Contribution to journalArticlepeer-review

Abstract

Our studies have demonstrated that TS patients show a high degree of sensitivity to butyrophenone blockade of dopaminergic receptors. The clinical response to extremely low serum levels of haloperidol includes sedating side effects, as well as therapeutic effects. These clinical changes are associated with significant increases in CSF HVA levels, which were abnormally decreased before treatment. CSF HIAA levels tended to be normal and did not change with haloperidol treatment. These results lend additional support to the hypothesis that TS is related to supersensitivity of dopaminergic receptors.

Original languageEnglish (US)
Pages (from-to)177-183
Number of pages7
JournalAdvances in neurology
Volume35
StatePublished - Dec 1 1982
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical symptomatology, CSF neurotransmitter metabolites, and serum haloperidol levels in Tourette syndrome.'. Together they form a unique fingerprint.

Cite this